פמטרקסד - Pemetrexed

פמטרקסד - Pemetrexed
פמטרקסד
התוויות	Alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

שם מסחרי

פמטרקסד - Pemetrexed
שמות מסחריים	®ALIMTA

פמטרקסד
קבוצה פרמקולוגית (ATC)	"Folic Acid Analogues"
סל הבריאות	כלול
התוויות	Alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
שם יצרן	LILLY FRANCE S.A.S., FRANCE
שם בעל הרישום	ELI LILLY ISRAEL LTD
יוצר הערך	מערכת ויקירפואה